biomee ApS: Financial statements 2023
CVR: 29829586
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
biomee ApS (CVR 29829586) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 7,518,821 and a net result of DKK 7,867,031 compared with DKK 3,602,319 the year before. That is an increase of 111.7% compared with the year before. Equity in the 2023 report amounted to DKK 11,676,959. The solvency ratio was 93.9%.
- Gross Profit
- DKK 7,518,821
- Profit/Loss
- DKK 7,867,031
- Equity
- DKK 11,676,959
- Total Assets
- DKK 12,433,547
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 7.5 mio. | 7.9 mio. | 11.7 mio. | - |
| 2022 | - | 3.6 mio. | 3.6 mio. | 3.8 mio. | - |
| 2021 | - | 8.6 mio. | 7.8 mio. | 208 t. | - |
| 2020 | - | -461 t. | -2.8 mio. | -57.6 mio. | - |
| 2019 | - | -273 t. | -2.4 mio. | -54.8 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Biomee ApS has published its annual report for 2022. Gross profit came to DKK 3,551,834, and the net result was DKK 3,602,319.
About biomee ApS
biomee ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named DRUG DELIVERY SOLUTIONS ApS and TOXICELL ApS. The management consists of Trine Ahlgreen. The company is owned by MC2 Therapeutics A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 4,813,840 and a net result of DKK 6,548,744 compared with DKK 5,547,134 the year before. Equity in the 2025 report amounted to DKK 23,772,837.